Direct compression of recombinant Protein A API into a monolithic tablet is attempted with a low-shear tumble blender to protect the protein from shear-induced aggregation. A typical investigational composition comprises 10–15 wt% recombinant Protein A, 60–70 wt% amorphous mannitol DC, 15–20 wt% microcrystalline cellulose PH102, 2–4 wt% croscarmellose sodium, and 0.5–1.0 wt% sodium stearyl fumarate. The bulk blend is passed through a 600 µm mesh screen. Blend uniformity is verified by sampling 10 locations with acceptance of 90–110% label claim and RSD ≤5.0% under USP 905. Tablet compression is run on a 16-station rotary press at 25–35 rpm. Main compression force is set to 6–12 kN with pre-compression at 1.5–3.0 kN. Hardness target is 40–80 N measured by a Schleuniger 6D tester. Friability limit is ≤1.0% after 100 rotations per USP 1216. Disintegration is ≤15 min in 900 mL water at 37±2°C per USP 701. The finished tablets are film-coated with a PVA-based coating suspension to 3.0–4.0% weight gain in a perforated pan coater, inlet air temperature 55–65°C. Bed temperature is maintained at 30–38°C during coating to prevent protein unfolding in the tablet core. On a production-scale campaign, sticking to the upper punch was observed when sodium stearyl fumarate content fell below 0.5 wt%; increasing to 0.75 wt% eliminated visible picking but prolonged disintegration by 2–3 min. Routine batches therefore use 0.75 wt% lubricant. If moisture in the mannitol DC exceeds 0.5%, the protein may become tacky during compression; pre-drying in a vacuum oven at 35°C for 12 h is required when storage relative humidity exceeds 60%. Systemic absorption after oral dosing of a full-length recombinant Protein A, approximately 42 kDa, is not supported by published data; the oral tablet is therefore evaluated only for local gastrointestinal exposure or as a research vehicle. The terminal finished product is an oval tablet in cold-form aluminum blister with desiccant.

What Limits Lyophilization Cycle Design for Injectable Recombinant Protein A?

Lyophilization of recombinant Protein A requires a formulation that minimizes aggregation during freeze concentration. A typical injectable solution contains 5.0 mg/mL recombinant Protein A, 20 mM histidine buffer pH 6.0, 5.0% w/v trehalose dihydrate, and 0.02% w/v polysorbate 20. The solution is filtered through a 0.22 µm PVDF membrane prior to filling into 6R Type I glass vials with a fill volume of 2.0 mL. Vials are partially stoppered with bromobutyl stoppers and loaded onto a shelf lyophilizer. The product-specific collapse temperature must be measured by freeze-dry microscopy prior to cycle scale-up; published data for this specific recombinant Protein A formulation is limited. A conservative cycle applies freezing to −45°C at 0.5°C/min, holding for 120 min. Annealing is performed at −20°C for 90 min to crystallize mannitol if present; for trehalose-only formulations, annealing may be omitted. Primary drying is performed at a shelf temperature of −20°C and chamber pressure of 80 mTorr for 36–48 h. Secondary drying is performed at 25°C and 50 mTorr for 6–10 h until residual moisture reaches ≤1.0% by USP 921 Karl Fischer. Reconstitution with sterile water for injection to 2.0 mL should produce a clear to slightly opalescent solution with pH 6.0±0.3. Subvisible particulate matter is controlled to ≤6000 particles per container for ≥10 µm and ≤600 for ≥25 µm per USP 788. The lyophilized cake must retain intact structure; collapse or meltback indicates an invalid batch. Terminal sterilization is not applied because steam or radiation damages protein structure; aseptic filtration followed by lyophilization is mandatory. Container closure integrity after capping is verified by vacuum decay per ASTM F2338-09. Stability-indicating SE-HPLC is used to monitor aggregate levels against a release limit of ≤5.0% high-molecular-weight species. Endotoxin content is controlled to ≤0.5 EU/mg per USP 85. Host-cell protein and residual DNA limits are set per ICH Q6B. On a production lyophilizer with 12 m² shelf area, edge vials dry faster than center vials; chamber pressure mapping is required to avoid collapse at the edge. Vial thermocouples are inserted into edge and center positions; product temperature should remain below collapse temperature for 10 h after primary drying begins. Condenser capacity must exceed total water load by 20%. Shelf temperature ramp rates above 1.0°C/min during secondary drying can crack the cake. The terminal finished product is a single-dose lyophilized injection presentation.

Capsule filling of recombinant Protein A demands stricter moisture control than direct compression because the protein is filled in contact with a hygroscopic shell. A capsule feasibility lot uses a size 0 HPMC shell to avoid gelatin cross-linking with residual aldehydes. The powder blend comprises 8–12 wt% recombinant Protein A, 70–80 wt% spray-dried lactose monohydrate, 10–15 wt% microcrystalline cellulose PH112, 0.5 wt% magnesium stearate, and 0.5 wt% colloidal silicon dioxide. Blending is performed in a low-shear V-shell blender at 25 rpm for 10 min. The final blend is filled on a Zanasi Z12 capsule machine at 30–60 cycles/min with a target fill weight of 250 mg. Capsule weight variation is assessed per USP 905 acceptance value ≤15. Moisture content of the shell is maintained at 4.0–8.0%; desiccant canisters are added when packout is expected to exceed 7 days. At 60% RH during capsule filling, the HPMC shell softened and caused dented caps; dehumidification to 30–35% RH restored machine efficiency. The finished capsules are enteric-coated only if a gastro-resistant profile is justified by local action; systemic absorption is not supported. Dissolution testing per USP 711 with 900 mL of pH 6.8 phosphate buffer at 37±0.5°C and paddle speed 50 rpm is used for process verification, not as a biowaiver surrogate for a systemic effect. If a reducing-sugar excipient is used, a stability-indicating RP-HPLC method monitors glycation at 40°C/75% RH over 6 months. The terminal product is a band-sealed HPMC capsule in PVC-PVDC blister with desiccant.

When Recombinant Protein A Is Processed into Oral Granules in a Fluid-Bed

Fluid-bed granulation is selected when the API must be dispersed in a liquid for oral administration. The granulation charge consists of 300 g recombinant Protein A, 300 g mannitol 25, and 40 g pregelatinized starch. The binder solution is 5.0% w/v povidone K30 in purified water, sprayed through a top-spray Glatt GPCG-5 with inlet air temperature 55–60°C, product temperature 30–35°C, spray rate 10–15 g/min, and atomizing pressure 1.2 bar. At a spray rate above 15 g/min, bed choking was observed on a Glatt GPCG-5; particle size distribution shifted to oversized granules and product temperature dropped below 30°C, indicating over-wetting. The spray rate is therefore capped at 12 g/min for routine production. Drying continues until loss on drying reaches 1.5–2.5%. Particle size retention above 150 µm is controlled to 70–80%; oversized granules are passed through a 1000 µm screen. The final granules are filled into aluminum stick-packs at 1.0 g per sachet. Moisture is measured by Karl Fischer per USP 921. Sachet seal integrity is tested at 300 mmHg vacuum per ASTM D3078-02. Seal width is maintained at 1.0–2.0 mm. Uniformity of mass is per USP 905. The terminal product is an oral granule for reconstitution; dissolution is not applicable until reconstitution. Reconstituted suspension viscosity should remain below 50 cP at 25°C to allow passage through a 10 Fr enteral tube.

Filtration-Train Design Controls Aggregation in Recombinant Protein A Bulk Solutions

Bulk sterile filtration of recombinant Protein A is performed prior to aseptic filling. The solution is held at 5±3°C in a jacketed stainless vessel. A 0.45 µm polyethersulfone prefilter removes particulate. A 0.22 µm sterilizing-grade PVDF or PES filter is then used. The maximum pressure across the sterilizing filter is ≤1.0 bar; constant-pressure rather than constant-flow operation reduces protein aggregation. Filter capacity is evaluated with a Vmax test at 2–8°C; protein solutions with high aggregate content may prematurely block the membrane. Bubble point and diffusive flow integrity tests are performed per the sterilizing filter manufacturer’s validated procedure; bacterial retention is qualified per ASTM F838-20. At 2–8°C, prefilter differential pressure above 0.5 bar before the sterilizing filter indicates an oversized or aggregated batch; such bulk is held for SE-HPLC analysis before release. The filtered bulk is filled immediately into sterilized containers. Hold time between filtration and filling should not exceed 4 h unless validated; after 24 h, aggregate content may increase by SE-HPLC. The terminal finished product is a sterile filtered bulk solution, not a terminal-sterilized dosage form.

Prefilled Syringe Compatibility and Subcutaneous Injection Parameters

Protein A solution in a prefillable syringe must be evaluated for protein-silicone oil interaction. A formulation with 10.0 mg/mL recombinant Protein A in 10 mM citrate, 130 mM sodium chloride, pH 5.5 is filled into a 1.0 mL long staked-needle glass syringe per ISO 11040-4. The plunger stopper is bromobutyl with fluoropolymer coating. Fill volume is 0.5 mL. The filled syringes are inspected for visible particles under USP 790; subvisible particles are measured per USP 788. Silicone oil droplets may adsorb protein and induce aggregation; if particle counts exceed 600 particles ≥25 µm per container at 2–8°C over 14 days, a silicone-free syringe system or polysorbate 0.01% w/v addition is required. Break-loose force and glide force are measured with a texture analyzer at 10 mm/min; break-loose force should not exceed 25 N and glide force should remain below 15 N. In one batch, silicone-free glass syringes without a fluoropolymer plunger coating produced erratic glide force and break-loose force greater than 30 N; fluoropolymer-coated stoppers brought force into the limit. The filled syringes are vacuum-stoppered and stored needle-down; this orientation reduces droplet accumulation at the needle hub. Terminal sterilization is not applied to protein solutions; aseptic filtration through 0.22 µm is followed by filling in a Grade A environment per ISO 13408-1 and ISO 14644-1 Class 5. The terminal product is a single-dose prefilled syringe for parenteral administration.

In a cartridge configuration, the solution viscosity of recombinant Protein A at neutral pH is a limiting factor for auto-injector performance. A 20.0 mg/mL formulation in 10 mM histidine, pH 6.0, with 4.0% w/v trehalose and 0.02% w/v polysorbate 20 is filled into a 3.0 mL Type I glass cartridge with a plunger stopper. Viscosity is measured at 25°C using a cone-and-plate viscometer at a shear rate of 100 s−1; values above 20 cP require reformulation because auto-injector spring force typically cannot maintain a 10 s injection time. At 20.0 mg/mL, the formulation may exceed 20 cP if trehalose is increased to 8.0% w/v; a lower trehalose level and a higher buffer concentration may be required. The cartridge is sealed with an aluminum crimp cap and a pierced septum. The filled cartridge is stored at 2–8°C and inspected for subvisible particles at release and at 14 days under USP 788. Needle penetration force and dose accuracy are verified using a test fixture calibrated to deliver 0.5 mL per actuation in 8–12 s; delivered volume accuracy is checked per ISO 11608-1. The terminal product is a single-dose cartridge for use with a compatible auto-injector.